Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results
Silence Therapeutics plc, (NASDAQ:SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the third quarter ended September 30, 2026, and provided an update on other recent business achievements.Recent Business Highlig…